Skip to main content
Clinical Trials/CTRI/2023/11/059391
CTRI/2023/11/059391
Not yet recruiting
Phase 2

To compare the efficacy of Topical Beta blocker (0.5% Timolol Maleate) and Ultrapotent Corticosteroid (0.05% Clobetasol Propionate) in the treatment of superficial infantile Capillary Hemangioma (ICH) via Randomized Control Trial: A Single Centre Pilot Study - Nil

All India Institute of Medical sciences, Raebareli, U.P.0 sites0 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 2
Status
Not yet recruiting
Sponsor
All India Institute of Medical sciences, Raebareli, U.P.

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • All children less than \<36 months of age having clinical and color Doppler\-proven infantile capillary hemangioma (ICH).
  • 1\. Superficial ICH on Doppler, including mucosal surfaces, and ulcerated ICH
  • 2\. Size of lesion \> 1\.5 Cm
  • 3\.No H/O prior tt for ICH
  • 4\. Patients at risk of adverse effects of systemic beta\-blockers like Cardiac arrhythmias, first\-degree heart block; recovered pts of cardiogenic or hypotensive shock, sinus bradycardia, Asthma, history of hypoglycemia, birth weight \< 2500 g would be included.

Exclusion Criteria

  • 1\. Age at the time of enrolment is \>36 months
  • Dermal invasive ICH
  • 2\. Life\-threatening ICH
  • 3\. Persistent arrhythmias, wheezing, heart failure
  • 4\. Associated Visceral vascular (liver/ renal/brain) lesions
  • 5\. Patients Having Raynaud phenomena
  • 6\. Bradycardia below the age\-specific range for normal
  • 7\. Low blood pressure according to age\-specific ranges for normal
  • 8\. known case of Pheochromocytoma
  • 9\. Breast\-feeding mothers who are on treatment with oral propranolol

Investigators

Sponsor
All India Institute of Medical sciences, Raebareli, U.P.

Similar Trials